Madrigal Pharmaceuticals, Inc. (MDGL) stock
MDGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/304% above fair value
$421.99−1.97 (-0.46%)
Close on Nov 17, 2026Market cap $9.75BP/E –Yield –
Madrigal Pharmaceuticals price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Madrigal Pharmaceuticals's price to book ratio was 19.1× on Nov 11, 2026, against 21.7× a year earlier. Over the last 5 years it ranged from 4.1× to 465.3×, with a median of 14.6×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 19.1× | −2.0 |
| 2025 | Dec 31, 2025 | 21.1× | +12.5 |
| 2024 | Dec 31, 2024 | 8.7× | −183.7 |
| 2023 | Dec 29, 2023 | 192.3× | −272.9 |
| 2022 | Dec 30, 2022 | 465.3× | +459.2 |
| 2021 | Dec 31, 2021 | 6.1× | +0.1 |
| 2020 | Dec 31, 2020 | 5.9× | +2.7 |
| 2019 | Dec 31, 2019 | 3.2× | −0.4 |
| 2018 | Dec 31, 2018 | 3.6× | −17.5 |
| 2017 | Dec 29, 2017 | 21.1× | +16.5 |
| 2016 | Dec 30, 2016 | 4.6× | +3.9 |
| 2015 | Dec 31, 2015 | 0.7× | −2.2 |
| 2014 | Dec 31, 2014 | 2.8× | −17.4 |
| 2013 | Dec 31, 2013 | 20.2× | +6.1 |
| 2012 | Dec 31, 2012 | 14.1× | +6.5 |
| 2011 | Dec 30, 2011 | 7.7× | +0.8 |
| 2010 | Dec 31, 2010 | 6.8× | – |
See a number that looks wrong?